Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-4 study of KTE-X19 in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma
NL-OMON54583Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), mature B-cell lymphoma, sponsored by Kite Pharma. Started Sep 2018; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON54583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54583.